Trial Profile

First in human phase I clinical trial assessing GT02329 in Parkinson's disease

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 11 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GT-02329 (Primary)
Indications Parkinson's disease
Focus Adverse reactions; First in man
Sponsors Gain Therapeutics

Most Recent Events

11 Feb 2022 New trial record
04 Feb 2022 According to Gain Therapeutics media release, the company will submit the regulatory dossier to the Human Research Ethics Committee in Australia to initiate this trial

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com